1
|
Rodriguez M, Fernandez-Miranda I, Mondejar R, Capote J, Rodriguez-Pinilla S, Cereceda L, Alonso R, Cordoba R, Provencio M, Martin-Acosta P, Sanchez A, Pedrosa L, Gómez S, Piris-Villaespesa M, Garcia-Cosio M, Quero C, Llanos M, Barcena C, Fraga M, Camacho F, Castro Y, Garcia J, Mollejo M, Climent F, Mayordomo E, Bacalari E, Olmedilla G, Sánchez-Beato M, Piris M. DIFFUSE LARGE B-CELL LYMPHOMA SURVIVAL PROGNOSTICATION, A COMPARATIVE ANALYSIS OF CELL OF ORIGIN VS. MYC/BCL2 EXPRESSION. Hematol Oncol 2019. [DOI: 10.1002/hon.15_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Rodriguez
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - I. Fernandez-Miranda
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - R. Mondejar
- Haematology; Hospital Universitario Virgen del Rocío, Sevilla; Spain
| | - J. Capote
- Medical Oncology; Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - S. Rodriguez-Pinilla
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - L. Cereceda
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - R. Alonso
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - R. Cordoba
- Haematology; Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - M. Provencio
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - P. Martin-Acosta
- Pathology; Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - A. Sanchez
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - L. Pedrosa
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - S. Gómez
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | | | - M. Garcia-Cosio
- Haematology; Instituto de Investigación Hospital Ramón y Cajal; Madrid Spain
| | - C. Quero
- Medical Oncology; Hospital Universitario Virgen de la Victoria; Málaga Spain
| | - M. Llanos
- Medical Oncology; Hospital Universitario de Canarias; Santa Cruz de Tenerife Spain
| | - C. Barcena
- Pathology; Instituto de Investigación Hospital 12 de Octubre; Madrid Spain
| | - M. Fraga
- Pathology; Hospital Clínico Universitario de Santiago-CHUS, Santiago de Compostela; A Coruña Spain
| | - F. Camacho
- Pathology; Hospital Universitario de Getafe; Madrid Spain
| | - Y. Castro
- Pathology; Hospital Universitario Príncipe de Asturias; Madrid Spain
| | - J. Garcia
- Pathology; Hospital MD Anderson Cancer Center; Madrid Spain
| | - M. Mollejo
- Pathology; Hospital Virgen de la Salud; Toledo Spain
| | - F. Climent
- Pathology; Hospital Universitario de Bellvitge; Barcelona Spain
| | - E. Mayordomo
- Pathology; Hospital Universitario y Politécnico de La Fe; Valencia Spain
| | - E. Bacalari
- Pathology; Hospital Universitario La Paz; Madrid Spain
| | - G. Olmedilla
- Pathology; Hospital Universitario La Paz; Madrid Spain
| | - M. Sánchez-Beato
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - M. Piris
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| |
Collapse
|
2
|
Diaz-Garcia C, Herraiz S, Such E, Villamon E, Mayordomo E, Sanz J, Pellicer A. Evaluation of anti-leukemic in vitro treatment with dexamethasone of ovarian cortex prior to transplantation. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Sanz J, Arango M, Senent L, Jarque I, Montesinos P, Sempere A, Lorenzo I, Martín G, Moscardó F, Mayordomo E, Salavert M, Cañigral C, Boluda B, Salazar C, López-Hontangas JL, Sanz MA, Sanz GF. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 2013; 49:397-402. [PMID: 24292521 DOI: 10.1038/bmt.2013.190] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 09/06/2013] [Accepted: 09/30/2013] [Indexed: 11/09/2022]
Abstract
We analyzed the incidence, clinicopathological features, risk factors and prognosis of patients with EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD) in 288 adults undergoing umbilical cord blood transplantation (UCBT) at a single institution. Twelve patients developed proven EBV-PTLD at a median time of 73 days (range, 36-812). Three-year cumulative incidence (CI) of EBV-PTLD was 4.3% (95% CI: 1.9-6.7). All patients presented with extranodal involvement. Most frequently affected sites were the liver, spleen, central nervous system (CNS), Waldeyer's ring and BM in 7, 6, 4, 3 and 3 patients, respectively. One patient had polymorphic and 11 had monomorphic EBV-PTLD (7 diffuse large B-cell lymphomas not otherwise specified, 4 plasmablastic lymphomas). We confirmed donor origin and EBV infection in all histological samples. EBV-PTLD was the cause of death in 11 patients at a median time of 23 days (range, 1-84). The 3-year CI of EBV-PTLD was 12.9% (95% CI: 3.2-22.5) and 2.6% (95% CI: 0.5-4.7) for patients receiving reduced-intensity conditioning (RIC) and myeloablative conditioning, respectively (P<0.0001). In conclusion, adults with EBV-PTLD after UCBT showed frequent visceral and CNS involvement. The prognosis was poor despite routine viral monitoring and early intervention. An increased risk of EBV-PTLD was noted among recipients of RIC regimens.
Collapse
Affiliation(s)
- J Sanz
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - M Arango
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - L Senent
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - I Jarque
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - P Montesinos
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - A Sempere
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - I Lorenzo
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - G Martín
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - F Moscardó
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - E Mayordomo
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - M Salavert
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - C Cañigral
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - B Boluda
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - C Salazar
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - J L López-Hontangas
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - M A Sanz
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - G F Sanz
- Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| |
Collapse
|
4
|
Martí N, Martin JM, Mayordomo E, Calduch L, Jordá E. Cutaneous and pulmonary sarcoidosis in a patient with human immunodeficiency virus: a late feature of immune restoration syndrome. Clin Exp Dermatol 2010; 36:306-7. [DOI: 10.1111/j.1365-2230.2010.03929.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
5
|
Martinez-Rodriguez M, Ramos D, Mayordomo E, Soriano P, Llombart-Bosch A. Analysis of cribriform Gleason grade 3 in prostatic carcinoma. A histopathological and immunohistochemical study of 32 cases. Histopathology 2007; 51:717-9. [DOI: 10.1111/j.1365-2559.2007.02834.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Fritzsche F, Gansukh T, Borgoño CA, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, Diamandis EP, Dahl E, Kristiansen G. Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. Br J Cancer 2006; 94:540-7. [PMID: 16434994 PMCID: PMC2361186 DOI: 10.1038/sj.bjc.6602956] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Human kallikrein 14 (KLK14) is a steroid hormone-regulated member of the tissue kallikrein family of serine proteases, for which a prognostic and diagnostic value in breast cancer has been suggested. To further characterise the value of KLK14 as a breast tumour marker, we have carefully analysed KLK14 expression in normal breast tissue and breast cancer both on the RNA level by real-time RT-PCR (n=39), and on the protein level (n=127) using a KLK14-specific antibody for immunohistochemistry. We correlated KLK14 protein expression data with available clinico-pathological parameters (mean follow-up time was 55 months) including patient prognosis. KLK14 RNA expression as quantified by real-time RT-PCR was significantly more abundant in breast tumours compared to normal breast tissue (P=0.027), an issue that had not been clarified recently. Concordantly with the RNA data, cytoplasmic KLK14 protein expression was significantly higher in invasive breast carcinomas compared to normal breast tissues (P=0.003). Furthermore, KLK14 protein expression was associated with higher tumour grade (P=0.041) and positive nodal status (P=0.045) but was not significantly associated with shortened disease-free or overall patient survival time in univariate analyses. We conclude that KLK14 is clearly overexpressed in breast cancer in comparison to normal breast tissues and is positively associated with conventional parameters of tumour aggressiveness, but due to a missing association with survival times, the use of KLK14 immunohistochemistry as a prognostic marker in breast cancer is questionable.
Collapse
Affiliation(s)
- F Fritzsche
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - T Gansukh
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - C A Borgoño
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
| | - M Burkhardt
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - S Pahl
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - E Mayordomo
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - K-J Winzer
- Breast Cancer Center, Charité Universitätsmedizin, Berlin, Germany
| | - W Weichert
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - C Denkert
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - K Jung
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - C Stephan
- Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - M Dietel
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
| | - E P Diamandis
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
| | - E Dahl
- Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
| | - G Kristiansen
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany
- Breast Cancer Center, Charité Universitätsmedizin, Berlin, Germany
- Institute of Pathology, Department of Urology, Charité Universitätsmedizin, Berlin, Germany. E-mail:
| |
Collapse
|
7
|
Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 2006; 59:403-9. [PMID: 16484444 PMCID: PMC1860378 DOI: 10.1136/jcp.2005.028209] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Activated leucocyte cell adhesion molecule (ALCAM, CD166) is a cell surface member of the immunoglobulin superfamily. ALCAM expression has prognostic relevance in prostate and colon cancer. OBJECTIVE To evaluate ALCAM protein expression in breast cancer by immunohistochemistry and to correlate expression levels with clinicopathological data. METHODS 162 primary breast carcinomas with a mean clinical follow up time of 53 months were immunostained using a monoclonal ALCAM antibody. The staining was evaluated as an immunoreactive score (IRS) and grouped into low v high for both membranous and cytoplasmic staining. RESULTS Intraductal and invasive carcinomas showed a higher ALCAM expression (median IRS 4 and 6 respectively) than normal breast tissue (IRS 2). In univariate survival analyses a significant association of high cytoplasmic ALCAM expression with shortened patient disease-free survival (mean (SD) five year non-progression rate, 69.4 (4.6)% v 49.4 (11.1)%, p = 0.0142) was found. In multivariate analyses of disease-free survival times, high cytoplasmic ALCAM expression (relative risk (RR) = 2.086, p = 0.026) and nodal status (RR = 2.246, p = 0.035) were significantly associated with earlier disease progression, whereas tumour grading (RR = 1.6, p = 0.052) was of borderline significance. CONCLUSIONS The data suggest that strong cytoplasmic ALCAM expression in primary breast cancer, as detected by immunohistochemistry, might be a new marker for a more aggressive breast cancer biology.
Collapse
Affiliation(s)
- M Burkhardt
- Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Boscá MM, Pérez-Baylach CM, Solis MA, Antón R, Mayordomo E, Pons S, Mínguez M, Benages A. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006; 55:294-5. [PMID: 16407390 PMCID: PMC1856509 DOI: 10.1136/gut.2005.082057] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|